KO'KRAK SUT BEZI SARATONIGA CHALINGAN BEMORLARDA SUYAK METASTAZLARINI ANIQLASHNING KLINIK VA MORFOLOGIK AXAMIYATI

Admin bo'lib kirish (www.admin.slib.uz)

Tizim sinov (TEST) rejimida ishlamoqda! Murojat uchun @slib_support

Eski talqinga o'tish link

31 январ 2021

Asosiy til:Rus

KO'KRAK SUT BEZI SARATONIGA CHALINGAN BEMORLARDA SUYAK METASTAZLARINI ANIQLASHNING KLINIK VA MORFOLOGIK AXAMIYATI

Fan yo'nalishi:

61b9d06161b91.pdf

PDF

RE-HEALTH

Maqola chop etish see more

MAQOLA ANNOTATSIYASI

Sut bezi raki bilan kasallanish Butun dunyoda kundan kunga o’sib bormoqda. BDSST ma’lumotlariga ko’ra yiliga dunyo bo’ylab 1,4 milliondan ortiq bemorda sut bezi raki aniqlanadi. Shundan 3000 ga yaqini O’zbekiston Respublikasiga to’g’ri keladi. 50% dan to 70%gacha bemorlar kasallikni kechiktirilgan bosqichi bilan ya’ni mahalliy regional limfa tugunlarga yoki uzoq a’zolarga metastazlar bilan aniqlanadi. Sut bezi rakining uzoqlarga metastazlarining soni va xususiyatlari har xiligi bilan farqlanadi. 40%-80% holatlarda suyaklarga metastaz beradi. Sut bezi rakining suyaklarga tarqalishi 70% holatlarda uzoq metastazlar ko’rinishida bo’ladi. Sut bezi raki umurtqaga, qovurg’aga va oyoq suyaklariga metastaz beradi. Bu esa ko’pincha osteoblastic va osteolitik ko’rinishda kartikal qavatning destruksiyasi va materksning yo’qolishi bilan kichadi.

MUALIFLAR

Teglar

# метастаз# рак молочной железы# metastasis# breast cancer# протоковый рак# дольковый рак# остеобластический# ductal cancer# lobular cancer# osteoblastic# sut bezi raki# sut yo’llari raki# sut bo’laklari raki# osteoblastik

Maqolani baholang

0

0 ta

Maqola idintifikatorlari

ROI:

https://eroi.uz/11.0082/A0121-0115

DOI:

Mavjud emas

Foydalanilgan adabiyotlar

1. Bakhlaev I.E. The state of diagnosis of breast cancer in the Karelian ASSR / Bakhlaev I.E., Tolpinsky A.P., Novikova A.M., Bedov V.M. // Abstracts of the All-Union Symposium "Screening in the early detection of tumors of the reproductive system and conducting organ-preserving treatment. Kostroma, June 5-6, 1991. - L., 1991. - P.5.

2. Vozny E.K. and others. Some prognostic factors in the complex treatment of locally advanced breast cancer // Vopr. oncol. - 2000. - T. 46 - No. 6 - S. 732-736.

3. Demidov V.P. Mammary cancer. Combined and complex treatment of patients with malignant tumors / Demidov V.P., Ostrovtsev L.D., Volkova N.A. Ase N.Ya. // Ed. IN AND. Chissova. - M.: Medicine, 1989. - S. 207-235.

4. Zaridze D.G. Epidemiology and screening

5. Perez B.A. HER-2 as a prognostic, predictive, and therapeutic target in breast cancer. // Cancer Control. - 1999. - V. 6. - P. 233-240.

6. Robain M. Predictive factors of response to first line chemotherapy in metastatic breast cancer / Robain M., Pierga J.-Y., Laurence V., Jouve M. // Trial Institut Curie. - V.4. - P. 23-25 120

7. Roche H. High-dose chemotherapy for breast cancer: the French PEGASE experience / Roche H., Viens P., Biron P. et al. // Cancer control. - 2003.-V. 10.-Nl.-P., 42-47. 8. Silverstein MJ. The influence of margin width on local control of ductal

8. Silverstein MJ. The influence of margin width on local control of ductal carcinoma in situ of the breast / Silverstein MJ., Lagios M.D., Groshen S. et al. // N Engl J Med. - 1999. - V. 340. - P. 1455-1461.

9. URAZBAEV I. et al. DEVELOPMENT OF AGROTECHNICAL METHODS AND APPLICATION OF BIOMELIORANT PLANTS IN THE LOWER AREAS OF AMUDARYA //Journal of Critical Reviews. – 2020. – Т. 7. – №. 11. – С. 1327-1331.

10. Niyazova Z., Khegay L., Rakhmanov A. EVALUATION OF AN IRRITATING AND ALLERGIZING ACTION OF A BIOPELLICLE FOR THE TREATMENT OF PENETRATING EYE INJURIES //Journal of Critical Reviews. – 2020. – Т. 7. – №. 11. – С. 1321-1326.

11. Салахиддинов К. З. и др. Раневые покрытия–как эффективный метод лечения ожоговых ран.

12. Zebiniso N. et al. FEATURES OF PSYCHOLOGICAL REHABILITATION IN PATIENTS WITH EYE INJURIES.

Сыдиков А. А. и др. РЕЗУЛЬТАТЫ ПАТОМОРФОЛОГИЧЕСКОЙ ОЦЕНКИ ЭФФЕКТИВНОСТИ ПРИМЕНЕНИЯ ПЛЁНОЧНОГО БИОПОКРЫТИЯ «NOVACEL ZIYO» В ТЕРАПИИ ПРОНИКАЮЩИХ РАНЕНИЙ ГЛАЗ //Re-health journal. – 2020. – №. 3-2 (7).